Alar Pharmaceuticals Future Growth
Future criteria checks 0/6
Alar Pharmaceuticals's revenue is forecast to decline at 133.2% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 59.1% |
| Revenue growth rate | -133.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 32 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 120 | N/A | N/A | N/A | 1 |
| 9/30/2024 | 474 | 401 | 218 | 221 | N/A |
| 6/30/2024 | 469 | 418 | 251 | 254 | N/A |
| 3/31/2024 | 469 | 411 | 275 | 282 | N/A |
| 12/31/2023 | 469 | 383 | 397 | 404 | N/A |
| 9/30/2023 | 2 | -21 | 110 | 117 | N/A |
| 6/30/2023 | 1 | -34 | 104 | 110 | N/A |
| 3/31/2023 | 1 | -27 | 108 | 109 | N/A |
| 12/31/2022 | 1 | -20 | -34 | -33 | N/A |
| 9/30/2022 | N/A | -53 | -52 | -52 | N/A |
| 6/30/2022 | N/A | -69 | -70 | -69 | N/A |
| 3/31/2022 | N/A | -70 | -74 | -73 | N/A |
| 12/31/2021 | N/A | -64 | -65 | -63 | N/A |
| 9/30/2021 | 0 | -65 | -69 | -68 | N/A |
| 6/30/2021 | 1 | -65 | -73 | -72 | N/A |
| 3/31/2021 | 1 | -104 | -108 | -107 | N/A |
| 12/31/2020 | 1 | -143 | -142 | -142 | N/A |
| 9/30/2020 | 0 | -137 | -126 | -125 | N/A |
| 6/30/2020 | N/A | -131 | -109 | -109 | N/A |
| 3/31/2020 | N/A | -99 | -89 | -89 | N/A |
| 12/31/2019 | N/A | -68 | -69 | -69 | N/A |
| 12/31/2018 | 1 | -54 | -42 | -42 | N/A |
| 12/31/2017 | 1 | -21 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6785's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if 6785's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 6785's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6785's revenue is expected to decline over the next 3 years (-133.2% per year).
High Growth Revenue: 6785's revenue is forecast to decline over the next 3 years (-133.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6785's Return on Equity is forecast to be high in 3 years time